Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Mezigdomide

Review the clinical trials studying mezigdomide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-12 of 12

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: 17 locations
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 12 locations
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Status: Active
Location: 9 locations
A Study of Teclistamab and Mezigdomide for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 7 locations
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Status: Active
Location: 5 locations
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 5 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 8 locations
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients with Extramedullary Disease
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Mezigdomide plus Ixazomib and Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients with Relapsed Multiple Myeloma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma after CD38- and BCMA-Targeted Therapies
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio